Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Robert Plenge, head of Research at Bristol Myers Squibb, discusses his vision of sequential immunotherapy for autoimmune diseases — including multiple sclerosis.
CAR T cell therapies have revolutionized the treatment of some blood cancers. These drugs could now be opening up transformative opportunities in autoimmunity as well. By unleashing these engineered T cells on the out-of-control B cells underpinning various autoimmune disorders, drug developers hope to lay the foundations for long-term immune system resets. Unprecedented data in lupus has prompted a research race in that disease, and trials in multiple sclerosis (MS) are up and running too.